A class action lawsuit was filed against Chemours Co., alleging overstated Opteon product demand and unreliable 2026 financial guidance. Investors purchasing securities between February and August 202
Chemours Company faces a securities class action lawsuit alleging misleading statements regarding Opteon aftermarket demand by executives. Eligible investors purchasing shares during the specified per
Levi & Korsinsky alerts Chemours investors to the December 7, 2026 deadline for a securities class action alleging overstated Opteon refrigerant demand caused a stock drop. Investors with losses betwe
Kahn Swick & Foti LLC reminds Chemours investors of a securities class action lawsuit deadline of December 7, 2026, citing alleged nondisclosure regarding an 18% stock drop driven by refrigerant chann
Chemours faces a class action lawsuit alleging overstated Opteon demand compromised financial guidance. Investors purchasing securities between Feb and Aug 2026 are urged to join the case.
SBS Law announced a class action lawsuit against Chemours for alleged securities fraud regarding Opteon demand and 2026 guidance, urging eligible shareholders to join before the December 2026 deadline
A securities fraud class action has been filed against Chemours following an 18.63% stock drop linked to alleged misrepresentations of Opteon product demand. Investors have until December 7, 2026, to
Chemours Co. faces a securities class action lawsuit alleging overstated demand for Opteon products. Investors who purchased shares between February and August 2026 have until December 7, 2026, to see
Chemours Co. faces a securities class action lawsuit alleging undisclosed oversupply in the refrigerant aftermarket, resulting in an 18.6% stock drop and reduced EBITDA guidance. Investors have until
A law firm filed a class action against Chemours, alleging overstated demand for its Opteon products led to unreliable financial guidance. Investors buying securities during the specified period are u
Chemours investors must file by December 7, 2026, to join a securities fraud lawsuit alleging misleading claims about Opteon demand and financial guidance. The case follows a sharp stock decline after
Robbins LLP urges Chemours investors with losses between February and August 2026 to contact the firm regarding a class action lawsuit alleging overstated Opteon demand led to unreliable financial gui
Levi & Korsinsky LLP filed a securities class action against Chemours Co., alleging misleading statements on Opteon demand and EBITDA guidance between February and August 2026. Investors with losses d
Chemours faces a securities class action lawsuit alleging misrepresentation of Opteon refrigerant sales and financial guidance, causing excess inventory and a share price drop after its Q2 2026 report
Chemours faces securities fraud class action alleging overstated refrigerant demand, resulting in an EBITDA cut and 18.63% stock decline. Investors purchasing shares between February and August 2026 h
Chemours Co. faces a securities class action alleging overstated Opteon demand and poor financial guidance caused a stock drop. Investors may join the suit before the December 7, 2026 deadline.
The Law Offices of Frank R. Cruz filed a securities fraud class action against Chemours after its stock fell 18.63% due to revised guidance on Opteon product demand. Investors have until December 7, 2
A securities class action lawsuit has been filed against Chemours Co. alleging overstated Opteon product demand caused financial losses. Investors have until December 7, 2026, to join as lead plaintif
Levi & Korsinsky filed a securities class action against Chemours alleging fraud regarding Opteon product demand and 2026 financial guidance. Shareholders are urged to contact the firm before December
Levi & Korsinsky LLP notifies Chemours investors of a securities class action alleging $65 million in Opteon refrigerant sales were improperly shifted between fiscal years due to distributor overstock
Chemours Co faces a class action lawsuit alleging overstated demand for Opteon products and unreliable financial guidance. Investors purchasing securities between February and August 2026 are encourag
Levi & Korsinsky filed a securities class action against Chemours Co., alleging false statements on Opteon demand and 2026 financial guidance. Investors seeking recovery must contact the firm before t
A class action lawsuit was filed against Chemours Co alleging false statements regarding Opteon product demand and unreliable financial guidance for 2026.
Investors in Chemours Co may lead a class action lawsuit alleging the company overstated demand for Opteon refrigerants and issued unrealistic guidance, leading to an 18.63% stock decline.
Chemours faces a securities class action lawsuit alleging failure to disclose oversupply in the refrigerant aftermarket, leading to an 18% stock decline and reduced EBITDA guidance. Investors purchasi
Levi & Korsinsky LLP announced a December 7, 2026, lead plaintiff deadline for a securities class action against The Chemours Company. The lawsuit claims overstated Opteon refrigerant demand and chann
Chemours Co. faces a securities class action lawsuit alleging overstatement of refrigerant aftermarket demand, resulting in a significant stock decline and guidance cut. Investors are urged to contact
Faruqi & Faruqi, LLP reminds Chemours investors of the December 7, 2026 deadline to seek lead plaintiff status in a lawsuit alleging misleading statements about Opteon product demand caused a signific
Chemours faces a class action lawsuit over alleged overstated Opteon demand and lowered 2026 guidance, following a 19% stock decline due to oversupplied inventory channels.
Schall, Brown & Schwartz LLP filed a class action lawsuit against Chemours, alleging misleading claims about Opteon product demand and 2026 financial guidance. Shareholders purchasing shares between F
A class action lawsuit was filed against Chemours Co., alleging overstated demand for Opteon products and unreliable financial guidance. Investors may seek damages by contacting the firm before Decemb
Chemours Co faces a securities class action lawsuit concerning Opteon demand and 2026 financial guidance disclosures. While investors view the stock as undervalued at $13.61 versus an $18.56 fair valu
A securities fraud class action lawsuit alleges Chemours made misleading statements regarding Opteon product demand, causing a stock drop. Investors have until December 7, 2026, to file lead plaintiff
ChemBrief